Artwork

Contenuto fornito da Canadian Dermatology Association. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da Canadian Dermatology Association o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.
Player FM - App Podcast
Vai offline con l'app Player FM !

Ep 29 - COVID-19 Vaccines and Derm Patients

36:51
 
Condividi
 

Manage episode 373000485 series 2341876
Contenuto fornito da Canadian Dermatology Association. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da Canadian Dermatology Association o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.

"There really is no safety risk with any non-live vaccine to our patients on biologics. And the vast majority of studies state that the efficacy of vaccines is maintained for patients on biologic therapy."

In a timely interview, Dr Mark Kirchhoff joins JCMS Editor in Chief Kirk Barber to discuss the impact of the rollout of COVID-19 vaccines on Dermatology patients, including a look at what vaccines are approved or will be approved in the near future, what immunotherapies are used in dermatology and what is the evidence of their effect on vaccinations, and what are the potential risks and efficacies of the COVID-19 vaccines for patients on immunotherapies. Dr Kirchhof's analysis is based on an extensive data review for publication.

Dr. Mark Kirchhof is the Division Head of Dermatology in the Faculty of Medicine at the University of Ottawa and The Ottawa Hospital.

JCMS Author Interviews is produced by David McGuffin of Explore Podcast Productions.

Theme music is by Lee Rosevere.

  continue reading

83 episodi

Artwork
iconCondividi
 
Manage episode 373000485 series 2341876
Contenuto fornito da Canadian Dermatology Association. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da Canadian Dermatology Association o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.

"There really is no safety risk with any non-live vaccine to our patients on biologics. And the vast majority of studies state that the efficacy of vaccines is maintained for patients on biologic therapy."

In a timely interview, Dr Mark Kirchhoff joins JCMS Editor in Chief Kirk Barber to discuss the impact of the rollout of COVID-19 vaccines on Dermatology patients, including a look at what vaccines are approved or will be approved in the near future, what immunotherapies are used in dermatology and what is the evidence of their effect on vaccinations, and what are the potential risks and efficacies of the COVID-19 vaccines for patients on immunotherapies. Dr Kirchhof's analysis is based on an extensive data review for publication.

Dr. Mark Kirchhof is the Division Head of Dermatology in the Faculty of Medicine at the University of Ottawa and The Ottawa Hospital.

JCMS Author Interviews is produced by David McGuffin of Explore Podcast Productions.

Theme music is by Lee Rosevere.

  continue reading

83 episodi

Todos os episódios

×
 
Loading …

Benvenuto su Player FM!

Player FM ricerca sul web podcast di alta qualità che tu possa goderti adesso. È la migliore app di podcast e funziona su Android, iPhone e web. Registrati per sincronizzare le iscrizioni su tutti i tuoi dispositivi.

 

Guida rapida